3-(2-Phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as PPAR modulators for treating type 2 diabetes and arteriosclerosis

Details for Australian Patent Application No. 2004215673 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Goerlitzer, Jochen; Gretzke, Dirk; Wendler, Wolfgang; Keil, Stefanie; Falk, Eugen; Stapper, Christian; Glombik, Heiner; Schaefer, Hans-Ludwig

Agent Watermark

Pub. Number AU-B-2004215673

PCT Pub. Number WO2004/076427

Priority 103 08 355.3 27.02.03 DE

Filing date 19 February 2004

Wipo publication date 10 September 2004

Acceptance publication date 1 October 2009

International Classifications

C07D 263/32 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

15 September 2005 PCT application entered the National Phase

  PCT publication WO2004/076427 Priority application(s): WO2004/076427

22 December 2005 Assignment before Grant

  Aventis Pharma Deutschland GmbH The application has been assigned to Sanofi-Aventis Deutschland GmbH

1 October 2009 Application Accepted

  Published as AU-B-2004215673

28 January 2010 Standard Patent Sealed

15 September 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004215674-Method for producing the enantiomeric forms of cis 1,3-cyclohexanediol derivatives

2004215672-3-methyl-2- (3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohex anecarbonyl-amino butyric acid derivatives and related compounds as PPAR modulators for the treatment of type 2 diabetes and atherosclerosis